Financial results - NEOPHARM SRL

Financial Summary - Neopharm Srl
Unique identification code: 6363226
Registration number: J51/712/1994
Nace: 4773
Sales - Ron
3.472.671
Net Profit - Ron
60.956
Employee
31
The most important financial indicators for the company Neopharm Srl - Unique Identification Number 6363226: sales in 2023 was 3.472.671 euro, registering a net profit of 60.956 euro and having an average number of 31 employees. Firma isi desfasoara activitatea in domeniul Comert cu amanuntul al produselor farmaceutice, in magazine specializate having the NACE code 4773.

Sales, Profit, Employees, Debts, Capitals, Financial Results - Neopharm Srl

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Sales - EUR 1.704.546 1.485.961 1.568.263 1.728.924 1.729.786 2.395.580 2.560.539 2.553.024 2.945.067 3.472.671
Total Income - EUR 1.700.086 1.487.828 1.577.143 1.742.940 1.730.999 2.432.037 2.575.751 2.566.100 2.966.016 3.568.696
Total Expenses - EUR 1.645.257 1.459.989 1.552.634 1.703.490 1.705.082 2.333.886 2.441.807 2.468.188 2.886.720 3.490.405
Gross Profit/Loss - EUR 54.829 27.839 24.509 39.450 25.917 98.151 133.943 97.912 79.296 78.292
Net Profit/Loss - EUR 46.126 23.385 18.947 23.140 17.886 81.715 109.808 81.080 62.911 60.956
Employees 14 13 14 15 15 28 28 31 31 31
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity. The data show the company's evolution during this period, highlighting any increases or potential decreases recorded. In the last year of activity, the sales increased by 18.3%, from 2.945.067 euro in the year 2022, to 3.472.671 euro in 2023. The Net Profit decreased by -1.765 euro, from 62.911 euro in 2022, to 60.956 in the last year.

Check the financial reports for the company - Neopharm Srl

Rating financiar

Financial Rating -
Neopharm Srl

See the company's note based on the submitted financial data, relative to the industry of which it is a part.

Check Financial Rating
Limite de plata

Payment Limits -
Neopharm Srl

See the company's payment capacity for situations in which you conclude contracts with payment terms.

Check Payment Limits
Probabilitate de insolventa

Prob. of insolvency -
Neopharm Srl

It determines the risk of insolvency based on the submitted accounting balance.

Check Insolvency Probability
Rapoarte financiare

Financial Reports -
Neopharm Srl

Check all the financial reports of the company and know the risks in collaboration with it.

Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.

Debts, Equity, Inventories, Receivables, Accounts, Assets - Neopharm Srl - CUI 6363226

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Fixed Assets 66.195 131.670 111.525 108.838 103.553 153.385 139.947 209.683 213.211 214.798
Current Assets 806.115 690.351 617.361 811.298 799.192 894.209 1.025.581 899.648 1.048.885 1.180.413
Inventories 376.057 401.530 378.568 427.868 337.179 585.925 665.803 580.049 665.859 740.490
Receivables 314.066 206.483 142.286 301.310 427.813 264.628 319.136 270.542 351.838 410.696
Cash 20.860 27.376 96.506 82.120 34.200 43.656 40.642 49.058 31.188 29.228
Shareholders Funds 369.018 397.968 390.589 340.442 338.840 411.889 455.096 488.838 508.121 556.801
Social Capital 89.244 89.989 89.071 87.564 85.957 107.051 105.022 102.693 103.011 102.699
Debts 503.293 424.053 338.297 579.694 563.904 626.697 703.455 615.489 750.780 837.046
Income in Advance 0 0 0 0 0 9.009 6.977 5.003 3.194 1.365
Exchange rate - RON 4.9465 4.9315 4.9468 4.8371 4.7454 4.6535 4.5681 4.4908 4.445 4.4821
Main CAEN "4773 - 4773"
CAEN Financial Year 4773
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of 1.180.413 euro in 2023 which includes Inventories of 740.490 euro, Receivables of 410.696 euro and cash availability of 29.228 euro.
The company's Equity was valued at 556.801 euro, while total Liabilities amounted to 837.046 euro. Equity increased by 50.221 euro, from 508.121 euro in 2022, to 556.801 in 2023. The Debt Ratio was 60.0% in the year 2023.

Activate the Financial Reports subscription with unlimited access and check the evolution and current financial situation of any company.

Subscriptions Financial Reports

You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.

Subscription cost is per user. You can pay simultaneously up to 10 users.
RisCo Subscriptions offer the greatest flexibility in choosing the best services according to the needs of each user. These are structured into categories based on the type of service desired, as well as on different service contract periods: monthly, semi-annually, and annually. Check out the subscription offer for the best choices!

Reviews - Neopharm Srl

Comments - Neopharm Srl

Similar services useful for checking companies and business development.

Contacts Firms

Get the contact details for any company and get in touch with it.

Sectoral Studies

Knows the market and develops its own development strategies according to sectorial data.

Company Lists

Create lists of companies for your sales activity according to your own criteria.

Import - Export

Find importers and exporters according to the type of activity and the countries in which they carry it out.

Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.